Mol Pharm. 2025 Nov 3;22(11):6999-7009. doi: 10.1021/acs.molpharmaceut.5c01009. Epub 2025 Oct 21.
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) expresses epidermal growth factor receptors (EGFR) in 90% of cases. Here we studied PET/CT imaging of three clinically relevant HNSCC patient derived xenografts (PDX) with low (#61531), moderate (#73191) or high (#88955) EGFR expression in NRG mice using anti-EGFR [64Cu]Cu-DOTA-panitumumab F(ab’)2. We further assessed the effectiveness of β-particle-emitting [177Lu]Lu-DOTA-panitumumab F(ab’)2 for radioimmunotherapy (RIT) of these PDX. All PDX were visualized by PET/CT at 24 h postinjection (p.i.) of [64Cu]Cu-DOTA-panitumumab F(ab’)2. In addition, in mice with PDX #88955, an axillary lymph node metastasis was imaged by PET and lung metastases were imaged by SPECT/CT at 3 to 12 d p.i. of [177Lu]Lu-DOTA-panitumumab F(ab’)2. Tumor uptake of [64Cu]Cu-DOTA-panitumumab F(ab’)2 at 24 h p.i. was directly correlated with EGFR expression (6.7 ± 3.5%, 13.5 ± 2.5% and 16.7 ± 1.0% ID/g for PDX #61531, #73191 and #88955, respectively). Intravenous administration of 5.0 MBq (50 μg) of [177Lu]Lu-DOTA-panitumumab F(ab’)2 to healthy NRG mice caused no hematologic, liver or kidney toxicity or decrease in body weight. RIT with 4.0-5.0 MBq (50 μg) of [177Lu]Lu-DOTA-panitumumab F(ab’)2 decreased the tumor growth rate vs 0.9% NaCl by 2, 9 and 3.2-fold, respectively in mice with PDX #61531, #73191 and #88955 (P = 0.014, P < 0.001, P = 0.004). Treatment of mice with unlabeled DOTA-panitumumab F(ab’)2 did not decrease the tumor growth rate of PDX#61531 (P = 0.457) but modestly decreased the tumor growth rate of PDX #73191 by 1.3-fold (P = 0.024) and PDX #88955 by 1.4-fold (P = 0.027). RIT was EGFR-specific as irrelevant anti-HER2 [177Lu]Lu-DOTA-trastuzumab F(ab’)2 was not effective for treatment of PDX #73191 vs 0.9% NaCl (P = 0.282). RIT with [177Lu]Lu-DOTA-panitumumab F(ab’)2 was 3-fold more effective for treating moderately EGFR-expressing PDX #73191 than PDX #88955 with high EGFR expression. This may be explained by the human papilloma virus (HPV) positivity of PDX #73191 since HPV-positive HNSCC is more responsive to external radiation beam treatment. We conclude that [64Cu]Cu-DOTA-panitumumab F(ab’)2 and [177Lu]Lu-DOTA-panitumumab F(ab’)2 are a promising theranostic pair for PET/CT imaging and RIT of HNSCC.
PMID:41117373 | DOI:10.1021/acs.molpharmaceut.5c01009